



Madrid, June 19, 2024

MAKING SCIENCE GROUP, S.A. (the "Company") by virtue of the provisions of article 17 of Regulation (EU) No. 596/2014 on market abuse and article 227 of the consolidated text of the Securities Market Law, approved by the Royal Legislative Decree 4/2015, of October 23, and corresponding provisions, as well as in the corresponding provisions, as well as in Circular 3/2020 of the BME Growth segment of BME MTF Equity, informs you of the following:

OTHER RELEVANT INFORMATION

In Madrid, on June 17, 2024, at 9:00 a.m., an Ordinary General Meeting of shareholders of the Company was held at the registered office with an attendance of 69.61% of the share capital of the Company with voting rights. .

In this session, the agenda items of the call published on the BME Growth website as "other relevant information" on May 17, 2024, as well as on the website therein, were submitted for deliberation by the attendees. date, the following agreements having been unanimously adopted by those present:

- 1. Examination and approval of the Annual Accounts of the Company, including the Balance Sheet, the Profit and Loss Account, the Statement of Changes in Shareholders' Equity, the Statement of Cash Flows and the Report, as well as the Management Report corresponding to the year. social closed on December 31, 2023.***
- 2. Examination and approval of the proposal to apply the results of the fiscal year ended December 31, 2023.***

Distribution base 2023

Profit and losses (losses) -€2,227,384

Application

To negative results from previous years -€2,227,384

- 3. Examination and approval of the consolidated Annual Accounts of the Group, including the consolidated Balance Sheet, consolidated Profit and Loss***

Account, consolidated Statement of Changes in Shareholders' Equity, consolidated Statement of Cash Flows and consolidated Annual Report, as well as the Management Report corresponding to the fiscal year closed on December 31, 2023.

- 4. Examination and approval of the non-financial information statement for fiscal year 2023.***
- 5. Review and approval of the management of the Board of Directors during the year ended December 31, 2022.***
- 6. Authorization to the Board of Directors, in accordance with the provisions of article 297.1 b) of the Capital Companies Law, to increase the amount of share capital through monetary contributions up to the limit of 20% of the amount of share capital, within the maximum period of 5 years, on one or several occasions, and in the opportunity and amount that it considers appropriate. Within the maximum amount indicated, the Board of Directors is granted the power to exclude the pre-emptive subscription right up to the aforementioned maximum limit of 20% of the share capital.***
- 7. Reelection of Auditor of accounts of the Company and of the consolidated accounts of the Group, for the year ending December 31, 2024, of Grant Thornton, S.L.P., a sole proprietorship.***
- 8. Approval of the remuneration policy for the Board and executive directors for the year 2024.***

In accordance with the provisions of article 17 of the Bylaws, a maximum remuneration of the Company's directors is approved for the year ending December 31, 2024 of €980,000.

9. Delegation of powers.

10. Drafting, reading and approval, if applicable, of the minutes of the Meeting.

In compliance with the provisions of BME MTF Equity Circular 3/2020, it is expressly stated that the information communicated hereby has been prepared under the exclusive responsibility of the Company and its directors in current position.

Carefully,
CEO of Making Science Group, S.A.
José Antonio Martínez Aguilar